Literature DB >> 3428130

In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.

S Ripa1, F Mignini, M Prenna, E Falcioni.   

Abstract

Fifty-four isolates of Campylobacter jejunii, 91 isolates of Yersinia spp. and 56 isolates of Clostridium difficile, recovered from stools of patients with diarrhoea or other intestinal disturbances and from stools of asymptomatic patients receiving antibiotic therapy, were tested in vitro for susceptibility to rifaximin, rifampicin and neomycin. The in vitro antibacterial activities were found to be comparable against the aerobic bacterium; on the contrary, against microaerophilic and anaerobic bacteria rifaximin and rifampicin were much more effective than neomycin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428130

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  7 in total

1.  In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.

Authors:  J M Sierra; J Ruiz; M M Navia; M Vargas; J Vila
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Rifaximin for the treatment of acute infectious diarrhea.

Authors:  Kyoung Sup Hong; Joo Sung Kim
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

3.  Antibiotics for the treatment of irritable bowel syndrome.

Authors:  Robert J Basseri; Stacy Weitsman; Gillian M Barlow; Mark Pimentel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-07

4.  Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma.

Authors:  Kenichi Nomura; Yosuke Matsumoto; Naohisa Yoshida; Sawako Taji; Naoki Wakabayashi; Shoji Mitsufuji; Shigeo Horiike; Masuji Morita; Takeshi Okanoue; Masafumi Taniwaki
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

Review 5.  Antibiotics for irritable bowel syndrome: rationale and current evidence.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Curr Gastroenterol Rep       Date:  2012-10

Review 6.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

7.  Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.

Authors:  Steliana Huhulescu; Ulrich Sagel; Anita Fiedler; Verena Pecavar; Marion Blaschitz; Guenther Wewalka; Franz Allerberger; Alexander Indra
Journal:  J Med Microbiol       Date:  2011-02-03       Impact factor: 2.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.